nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-228-8-158-162nogr-2862Research ArticleОБЗОРREVIEWКомбинированная терапия гастроэзофагеальной рефлюксной болезни при коморбидности с функциональной диспепсиейCombination therapy of gastroesophageal reflux disease in comorbidity with functional dyspepsiaКаримовМ. М.KarimovM. M.noemail@neicon.ruЗуфаровП. С.ZufarovP. S.noemail@neicon.ruСобироваГ. Н.SobirovaG. N.noemail@neicon.ruhttps://orcid.org/0000-0002-2363-5215РустамоваМ. Т.RustamovaM. T.mamlakatrustamova2018@mail.ruКаримоваД. К.KarimovaD. K.noemail@neicon.ruХайруллаеваС. С.KhairullaevaS. S.noemail@neicon.ruГУ «Республиканский специализированный научно-практический медицинский центр терапии и медицинской реабилитации»РоссияRepublican Specialized Scientific and Practical Medical Center for Therapy and Medical RehabilitationRussian FederationТашкентская медицинская академияРоссияTashkent Medical AcademyRussian Federation20240302202508158162Copyright © Каримов М.М., Зуфаров П.С., Собирова Г.Н., Рустамова М.Т., Каримова Д.К., Хайруллаева С.С., 20252025Каримов М.М., Зуфаров П.С., Собирова Г.Н., Рустамова М.Т., Каримова Д.К., Хайруллаева С.С.Karimov M.M., Zufarov P.S., Sobirova G.N., Rustamova M.T., Karimova D.K., Khairullaeva S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2862

Комбинироваанное использование ингибиторов протонной помпы и прокинетиков при фармакотерапии ГЭРБ и ФД приводит к снижению изжоги и боли за грудиной. Однако, такие симптомы, как регургидация, отрыжка, чувство раннего насыщения и тяжесть после еды купировались неэффективно. Включение в комплекс лечения прокинетика домперидона в дозе 10 мг 3 раза в день способствовало более эффективной регрессии симптомов нарушения моторики пищевода и желудка.

It has been shown that in patients with GERD and functional dyspepsia, the use of proton pump inhibitors leads to a decrease in heartburn and pain behind the sternum. However, symptoms such as regurgitation, belching, feeling of early satiety and heaviness after eating were stopped ineffectively. The inclusion in the treatment complex of the prokinetic domperidone at a dose of 10 mg 3 times a day contributed to a more effective regression of symptoms of impaired motility of the esophagus and stomach.

гастроэзофагеальная рефлюксная болезньфункциональная диспепсияингибиторы протонной помпыпрокинетикиgastroesophageal reflux diseasefunctional dyspepsiaproton pump inhibitorsprokineticsReferencesDe Bortoli N., Martinucci I., Bellini M., Savarino E. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787-97.De Bortoli N., Martinucci I., Bellini M., Savarino E. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787-97.Domperidone IND Packet. US Food and Drug Administration. 2018. 17 p. Available at: https: //www.fda.gov/ downloads/drugs/ development approval process/how drugs are developed and approved/appro).Domperidone IND Packet. US Food and Drug Administration. 2018. 17 p. Available at: https: //www.fda.gov/ downloads/drugs/ development approval process/how drugs are developed and approved/appro).Drossman D. Rome III: The functional gastrointestinal disorders. - 3rd ed. - McLean, VA: Degnon Associates, Inc., 2006. pp. 369-418.Drossman D. Rome III: The functional gastrointestinal disorders. - 3rd ed. - McLean, VA: Degnon Associates, Inc., 2006. pp. 369-418.Keohane J., Quigley E. M. Functional dyspepsia and nonerosivereflux disease: clinical interactions and their implications. Med Gen Med. 2007;9(3):31.Keohane J., Quigley E. M. Functional dyspepsia and nonerosivereflux disease: clinical interactions and their implications. Med Gen Med. 2007;9(3):31.Ortiz A., Cooper C. J., Alvarez A. Cardiovascular Safety Profile and Clinical Experience with High-Dose Domperidone Therapy for Nausea and Vomiting. Am. J. Med. Sci. 2015;349 (5):421-424.Ortiz A., Cooper C. J., Alvarez A. Cardiovascular Safety Profile and Clinical Experience with High-Dose Domperidone Therapy for Nausea and Vomiting. Am. J. Med. Sci. 2015;349 (5):421-424.Parkman H.P., Jacobs M. R., Mishra A. Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects Digestive Diseases and Sciences. Dig. Dis. Sci. 2011;56 (1):115-124.Parkman H.P., Jacobs M. R., Mishra A. Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects Digestive Diseases and Sciences. Dig. Dis. Sci. 2011;56 (1):115-124.Schey R., Saadi M., Midani D. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Dig. Dis. Sci. 2016;61(12):3545-3551.Schey R., Saadi M., Midani D. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Dig. Dis. Sci. 2016;61(12):3545-3551.Wolfe M.M., Lowe R. C. Investing in the Future of GERD. J. Clin. Gastroenterol. 2007;41:209.Wolfe M.M., Lowe R. C. Investing in the Future of GERD. J. Clin. Gastroenterol. 2007;41:209.Yuan Y., Hunt R. H.Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am. J. Gastroenterol. 2008;103 (suppl 1):50. Abstract #128.Yuan Y., Hunt R. H.Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am. J. Gastroenterol. 2008;103 (suppl 1):50. Abstract #128.

The authors declare that there are no conflicts of interest present.